Jubilant Ingrevia Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Resilient volumes, margin hit from one-off shocks: Specialty Chemicals grew 26% YoY and Acetic Anhydride volumes rose 22%, but EBITDA fell sharply as an unprecedented coal supply shock, a catalyst change, and a flu-driven Nutrition demand collapse converged in a single quarter.
• The coal shock was the dominant P&L event: Government denial of FSA coal forced 100% imported coal at spot prices, costing ₹45 crore in the quarter, with partial carryover into Q2. Management calls it a one-time impact never seen before.
• Nutrition took a rare demand hit, not a structural one: Avian and Swine Flu in Europe and the U.S. crushed Niacinamide volumes in Animal Feed, an event management describes as unprecedented for Vitamin B3. Demand normalization is expected from late Q2, with full recovery in Q3.
• The capex engine is fully committed and on track: ₹2,050 crore of growth capex is committed through FY25, with three new facilities (CDMO GMP, CDMO non-GMP, Acetic Anhydride) commissioning in Q3 FY23 to drive the next leg of volume growth.
• What to watch next quarter: Whether FSA coal supply resumes September 1 as promised, the pace of Nutrition demand recovery in Europe and the U.S., and whether the Pyridines catalyst change truly was a one-off that reverses in Q2.

The Coal Shock: A One-Time Margin Event

• What happened: The government stopped supplying FSA coal to industries for a short-term period, forcing the Gajraula plant to import all its coal at much higher spot prices. The impact was ₹45 crore in Q1, with a partial carryover into Q2 because FSA coal was still unavailable as of the call date.
• Why it was not fully passed through: Management normally passes raw material cost increases to customers, but the speed and magnitude of this coal price spike were unprecedented, so only partial pass-through was achieved during the quarter.
• The fix is external and dated: FSA coal supply is expected to resume from September 1. If that holds, the headwind largely disappears from Q3 onward.
• Broader power and fuel context: Power and fuel costs were almost ₹100 crore higher YoY, partly passed on, with more pass-through expected in the coming quarter, though management hopes for normalization rather than permanent elevation.

Rajesh Srivastava: "The impact which has happened in quarter Q1, partly will also have in Q2. That is one-time impact which we have never seen in the past."

Nutrition: A Rare Demand Shock, Not a Structural Problem

• The disruption: Niacinamide (Vitamin B3) sales volumes in Animal Feed fell sharply because Avian and Swine Flu outbreaks in Europe and the U.S. suppressed demand. Management stated this was an unprecedented situation for the product, never seen before.
• The recovery path: The flu situation is improving and expected to normalize during the later part of Q2, with a real long-life demand situation returning in Q3. H2 FY23 volumes will be "definitely more than last year H2."
• Full-year volume reset: Because of the Q1 hit and partial Q2 impact, no volume growth is expected in FY23 over last year for Vitamin B3.
• Capacity expansion continues regardless: Niacinamide capacity is being added because it will be needed in H2 FY23 and beyond, with expansion happening this year and mainly next year, signaling confidence in the demand recovery.
• Food and Cosmetics held up: Volumes in the Food and Cosmetics segment continued to see positive trends YoY, and the strategy to maximize Niacinamide share in niche segments is getting positive results.
• Premix contribution is small: Specialty Premixes are not yet a significant contributor to the Nutrition business, per management.

Rajesh Srivastava: "Vitamin B3 is a very important product, which we have never seen this situation what we have seen in Q1."

Specialty Chemicals: Strong Demand, Two One-Off Supply Hits

• Topline momentum intact: Revenue grew 26% YoY driven by higher volumes across product segments, with healthy demand from agrochemical customers and oil field chemicals. The China-plus-one strategy is generating positive traction from both domestic and international customers.
• The two QoQ drags beyond coal: Quarter-on-quarter EBITDA reduction had two additional one-off factors. First, China's 2.5–3 month lockdown impacted export volumes. Second, an unplanned catalyst change in the Pyridines plant, an event that occurs once every 6–7 years, happened in Q1 and reduced Pyridine volumes.
• Recovery already visible: Pyridine volumes are coming back better, and China is now picking up in Specialty. The QoQ gap was described as mostly one-off.
• Diketene plant ready: The newly commissioned Diketene plant is fully stabilized and has achieved designed capacity. Approval processes are ongoing, some volumes have started, and real capacity utilization is expected from Q2 end or Q3 onward.
• CDMO progress: Deliveries of recently contracted CDMO products are happening on time, all other CDMO products are moving as per plan, and the pipeline is healthy. New GMP and non-GMP facilities expected in Q3 FY23 will help capture growing demand.
• Agro Actives pipeline building: Products including Fluroxypyr and Pyriproxyfen are listed on the website and under customer approval, with regulatory approvals being pursued in various countries. The greenfield plant will be ready by Q4 FY24, with sales expected from FY25 onward.

Rajesh Srivastava: "This unprecedented increase of coal unfortunately was not fully passed on. We are definitely capable to pass on the prices, but this was really unprecedented."

Chemical Intermediates: Normalization Masks Strong Anhydride Story

• The headline decline is normalization: On a YoY basis, the segment witnessed a normalized market situation coupled with lower acetic acid prices, which is reflected in both revenue and EBITDA. The prior-year period had benefited from an unusually favorable market.
• Acetic Anhydride is the hidden strength: Strong demand drove 22% volume growth YoY, with market share in Europe improving significantly and continuing to grow. New uses for Anhydride are consuming large volumes, and demand is much more than available volume.
• Margins were volume-driven, not inventory-driven: Management explicitly corrected an analyst who assumed inventory gains: there was no inventory gain in Q1. There was actually a loss from the Acetic Acid price decline (from ~\$740 to ~\$540). Strong Anhydride margins were purely volume-driven, with strong and continuing volumes in Europe and maintained prices.
• QoQ margin optics explained: Q1 results benefited from a much lower inventory loss compared to Q4 FY22, which had depressed Chemical Intermediates profits. The comparative improvement boosted reported margins, but the underlying strength is real volume and pricing.
• New product traction: Good demand traction is emerging for Propionic Anhydride.
• European demand is not softening: Management sees no drop in consumption of its products in Europe. End uses are not very high energy-intensive, and the energy cost contribution to the finished product is not large, insulating demand from the European energy crisis.

Prakash Bisht: "Increase in net working capital is driven by short-term decision to maintain higher inventory to manage uncertainty of market and supply chain situation."

Capex, Mix Shift, and the Path to Margin Recovery

• The ₹2,050 crore plan is fully committed: Over Q1, ₹100 crore moved from "to be committed" to "committed": ₹75 crore in Specialty Chemicals, ₹25 crore in Chemical Intermediates. Three new facilities, CDMO GMP, CDMO non-GMP, and Acetic Anhydride, are likely to aid revenue growth and are expected to commission in Q3 FY23.
• The 65% mix ambition: Management is strategizing to improve the revenue mix of Specialty and Nutrition segments together to 65% by FY26 from 46% in FY22, believing this will be a key driver for overall margin improvements as these segments carry structurally better margins.
• Margin recovery timeline: Better margin profile is expected from the second half of FY23 as new capacities in Specialty and Nutrition come on stream and the one-off shocks (coal, catalyst, flu) reverse.
• Agro Actives is a FY25 story: Phase-1 investment is ₹200 crore with a 1.52x asset turn assumption. The greenfield plant will be ready by Q4 FY24, with sales starting FY25 subject to customer approvals and regulatory clearances. Phase-2 (herbicide and further insecticide expansion) is not yet announced.
• Debottlenecking continues: Ongoing debottlenecking of existing facilities is a continuous process beyond the major capex items highlighted.
• No oversupply risk seen: Management sees no oversupply situation in any of its product segments. Demand is growing, supporting both capacity expansion and pricing power.

Rajesh Srivastava: "We are fully committed towards our growth aspirations and we are excited to realize the emerging opportunities through our ongoing growth CAPEX plan of Rs. 2,050 crore during FY'22 to FY'25 period."

China-Plus-One and the Domestic Opportunity

• Two clear shifts observed: End-use customers are now producing more in India, improving consistency of domestic sales and neutralizing China competition. Second, for the same product, customers are preferring India over China for sourcing, increasing share of wallet.
• CDMO inquiry pipeline trending up: New inquiries for CDMO business are on an upward trend, driven by the China-plus-one diversification push from global customers.
• Domestic sales strength: Domestic sales were strong during the quarter, partly attributable to this structural shift in sourcing patterns.

Rajesh Srivastava: "If they have an option of China and India for the same product, they would prefer us to see sell more share."

Guidance & Commitments

Key Metrics